Back to results
US 2026/0092932 A1Published application
Methods and compositions for the detection, diagnosis and treatment of autism spectrum disorder
AssigneesThe Johnson Center for Child Health and Development, Board of Regents, The University of Texas System
InventorsLaura C. Hollenbeck, Dwight C. German, Jeon Lee, Jeremy A. Mathews
Life of this patent
Estimating the term…
Abstract
Disclosures herein are directed to methods and compositions for the detection of a panel of proteins as markers for ASD. Based on the results achieved from the methods disclosed herein, ASD can be diagnosed and suitable treatments for ASD may be designed and administered to the subject.
Claims20
A method of identifying enhanced risk of Autism Spectrum Disorder (ASD) in a subject comprising:
- (a) determining expression levels of a panel of ASD markers in a biological sample of the subject, wherein the panel of ASD markers are immunoglobulin D (IgD), soluble urokinase-type plasminogen activator receptor (suPAR), mitogen-activated protein kinase 14 (MAPK14), ephrin type-B receptor 2 (EPHB2), and dermatopontin (DERM);
- and
- (b) identifying an enhanced risk of ASD in the subject having a biological sample in which the expression levels of the panel of ASD markers are differentially expressed compared to expression levels of the ASD markers in a control biological sample from a subject not having Autism spectrum disorder (ASD);
- and
- (c) administering a treatment to the subject, wherein the treatment is a pharmaceutical therapy comprising any one or more of a selective serotonin re-uptake inhibitor (SSRI), a tricyclic, a psychoactive or anti-psychotic medication, an anti-anxiety medication, a stimulant, an anticonvulsant, a steroid, or any combination thereof.
2 more elements
A method for providing a treatment plan for a subject identified as having a higher risk of Autism Spectrum Disorder (ASD), comprising:
- a) determining an expression level of a panel of ASD markers in a biological sample from the subject, wherein the panel of ASD markers consists essentially of:
- immunoglobulin D (IgD),
- soluble urokinase-type plasminogen activator receptor (suPAR),
- mitogen-activated protein kinase 14 (MAPK14),
- ephrin type-B receptor 2 (EPHB2),
- dermatopontin (DERM),
- calcineurin,
- pleiotrophin (PTN),
- immunoglobulin-like transcript 2 (ILT-2);
- interleukin-6 receptor soluble alpha subunit (IL-6 sRa);
- eukaryotic translation initiation factor 4H (eIF-4H);
- collagen type VIII alpha 1 chain (CO8A1);
- and
- complement C5b,6 complex (C5b,6 complex);
- b) comparing the expression levels of the panel of ASD markers in the biological sample of the subject to expression levels of the panel of ASD markers in a control biological sample;
- c) identifying an enhanced risk of ASD in the subject having a biological sample with a decreased expression level of at least one, two, three, four, five, six, seven, eight, nine or all of IgD, MAPK14, EPHB2, DERM, eIF-4H, calcineurin, PTN, ILT-2, IL-6 sRa, and C5b,6 compared to the control biological sample, and (ii) an increased expression level of suPAR compared to the control biological sample, identifies an enhanced risk of ASD compared to the control biological sample;
- and
- d) preparing and administering a treatment plan for the subject, wherein the treatment plan for a subject identified as having an enhanced risk of ASD comprises administering a replacement or pharmaceutical therapy to the subject, wherein the pharmaceutical therapy is selected from the group consisting of:
- a selective serotonin re-uptake inhibitor (SSRI), a tricyclic, a psychoactive or anti-psychotic medication, an anti-anxiety medication, a stimulant, an anticonvulsant, a steroid, or any combination thereof.
16 more elements
A method of providing a treatment plan for Autism spectrum disorder (ASD) in a subject, the method comprising:
- (a) determining expression levels of a panel of ASD markers in a biological sample of the subject, wherein the panel of ASD markers comprises a group of ASD markers comprising:
- immunoglobulin D (IgD), soluble urokinase-type plasminogen activator receptor (suPAR), mitogen-activated protein kinase 14 (MAPK14), ephrin type-B receptor 2 (EPHB2), dermatopontin (DERM), and calcineurin;
- and
- (b) identifying an enhanced risk of ASD in the subject having a biological sample in which the expression levels of the panel of ASD markers are differentially expressed compared to expression levels of the ASD markers in a control biological sample from a subject not having Autism spectrum disorder (ASD), wherein the subject having a differentially expressed panel of ASD markers demonstrates one or more symptoms associated with ASD that is treatable with a pharmaceutical therapy;
- and
- (c) preparing and administering a treatment plan for the subject, wherein the treatment plan for a subject identified as having an enhanced risk of ASD markers comprises administering a pharmaceutical therapy comprising any one or more of a selective serotonin re-uptake inhibitor (SSRI), a tricyclic, a psychoactive or anti-psychotic medication, an anti-anxiety medication, a stimulant, an anticonvulsant, a steroid, or any combination thereof.
3 more elements
Dependencies are inferred from the claim text.